Monday, November 16, 2009

Another Vytorin Mess For Merck - Matt Herper

"How is it possible for a drug to have $4 billion in sales without any evidence of benefit?" says Harlan Krumholz, a cardiologist at Yale University. He said that the small size of the two imaging studies mean they couldn't render a clear verdict on Zetia. "But they don't instill any confidence in it either. "

Posted via web from Jack's posterous

No comments: